Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer’s Disease
The treatment of complex and multifactorial diseases constitutes a big challenge in day-to-day clinical practice. As many parameters influence clinical phenotypes, accurate diagnosis and prompt therapeutic management is often difficult. Significant research and investment focuses on state-of-the-art...
Main Authors: | Dimitrios Vlachakis, Eleni Papakonstantinou, Ram Sagar, Flora Bacopoulou, Themis Exarchos, Panos Kourouthanassis, Vasileios Karyotis, Panayiotis Vlamos, Constantine Lyketsos, Dimitrios Avramopoulos, Vasiliki Mahairaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/7/1627 |
Similar Items
-
Excitatory Neurons Derived from Human-Induced Pluripotent Stem Cells Show Transcriptomic Differences in Alzheimer’s Patients from Controls
by: Ram Sagar, et al.
Published: (2023-08-01) -
Polygene Risk Scores
by: James Woodward, et al.
Published: (2023-07-01) -
The False Dawn of Polygenic Risk Scores for Human Disease Prediction
by: Anthony F. Herzig, et al.
Published: (2022-07-01) -
Polygenic effects on the risk of Alzheimer’s disease in the Japanese population
by: Masataka Kikuchi, et al.
Published: (2024-02-01) -
A Systematic Review of Polygenic Models for Predicting Drug Outcomes
by: Angela Siemens, et al.
Published: (2022-08-01)